Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 17Recruiting 10Unknown 8Withdrawn 3Not yet recruiting 3Terminated 2Active not recruiting 2Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 1Nausea 1Gynecologic Cancer 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Interventional × Olanzapine × Clear all
NCT04503668 2025-06-18

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

University of Michigan Rogel Cancer Center

Phase 3 Terminated
62 enrolled 16 charts
Gynecologic

Gynecologic Cancer

NCT00124930 2012-01-19

Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer

AHS Cancer Control Alberta

Phase 3 Terminated
80 enrolled

Nausea, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡